Democratic Republic of the Congo (DRC)

ABSTRACTHuman monkey pox is an emerging viral zoonotic disease. This is caused by monkey pox virus. Monkey pox has a clinical presentation like flulike symptoms characteristic rash fever, malaise, back pain, and headache. Primarily monkey transmission to human is believed to occur through direct contact with infected animals (or) possibly by ingestion of inadequately cooked flesh. The review article mainly discuss about orthopox virus genes have been  shown to suppress anti-viral cell defenses, exploit host cell machinery and delay infection induced cell death. And control there are no licensed therapies to treat human monkey pox viral infection, however the small pox vaccine can protect against the disease. The management of monkey pox is mainly used this medications like Small Pox Vaccine, Cidofovir, Brincidofovir, Tecovirimat, Vaccinia Immune Globulin (VIG). Discontinuation of vaccination has given rise to increasing susceptibility to monkey pox viral infection. This lead to a fear of bioterrorism. Effective prevention limiting contact with infected patients (or) animal. Limiting the respiratory exposure to infected patients. Mortality and Morbidity rate of this virus is very rare conditions. This virus mainly prone to neonatal & pediatric patients, the hospital stay is minimum of 4 weeks. Keywords: Benign epidermal Monkey Pox (BEMP), Democratic Republic of the Congo (DRC), Monkey Pox Virus (MPV), Polymerase Chain Reaction (PCR), Immunoglobulin M (IgM), Center for Disease Control and Prevention (CDC), Fold Change Ratios (FCR), Ingenuity Pathway Analysis (IPA), Vaccinia Immune Globulin (VIG).